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Interleukin-17 and family members
Interleukin-17 (IL-17) is a 17 kDa protein that is secreted
as a dimer by a restricted set of cells, predominantly
activated human memory T cells or mouse αβTCR+CD4−
CD8− thymocytes [1–3]. Rouvier and colleagues have
cloned cytotoxic T lymphocyte-associated antigen-8 (rat
IL-17) from a T cell subtraction library [4] and mouse IL-17
was cloned from a thymus-derived, activated T cell cDNA
library [3]. Subsequently, the human counterpart of mouse
IL-17 was cloned by two independent groups [1,2,5].
Human IL-17 has 25% amino acid sequence homology to
mouse IL-17, as well as 72% homology to an open-
reading frame from the T lymphotropic herpes virus saimiri
(HVS13) and 63% homology to CTLA8 [2,4]. In addition
to IL-17 (IL-17A) another five members of the IL-17 family
have been discovered (IL-17B-F) by large-scale
sequencing of the human and other vertebrate genomes
(Table 1) [6].
The different IL-17 family members seem to have very
distinct expression patterns, suggesting distinct biological
roles. IL-17B is moderately expressed in several peripheral
tissues as well as immune tissues [7,8], and IL-17E is
expressed in various peripheral tissues [9]. Interestingly,
IL-17F has biological functions similar to those of IL-17(A)
and is also produced by activated monocytes [10,11].
This indicates that the IL-17 family might contribute to the
pathology of rheumatoid arthritis (RA) and other
inflammatory diseases not only through activated T cells
but also through activated monocytes/macrophages.
Further work will be required to determine the precise
mechanism of action of IL-17 and its family members such
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Abstract
Interleukin-17 (IL-17) is a T cell cytokine spontaneously produced by cultures of rheumatoid arthritis
(RA) synovial membranes. High levels have been detected in the synovial fluid of patients with RA.
The trigger for IL-17 is not fully identified; however, IL-23 promotes the production of IL-17 and a
strong correlation between IL-15 and IL-17 levels in synovial fluid has been observed. IL-17 is a
potent inducer of various cytokines such as tumor necrosis factor (TNF)-α, IL-1, and receptor
activator of NF-κB ligand (RANKL). Additive or even synergistic effects with IL-1 and TNF-α in
inducing cytokine expression and joint damage have been shown in vitro and in vivo. This review
describes the role of IL-17 in the pathogenesis of destructive arthritis with a major focus on studies in
vivo in arthritis models. From these studies in vivo it can be concluded that IL-17 becomes significant
when T cells are a major element of the arthritis process. Moreover, IL-17 has the capacity to induce
joint destruction in an IL-1-independent manner and can bypass TNF-dependent arthritis. Anti-IL-17
cytokine therapy is of interest as an additional new anti-rheumatic strategy for RA, in particular in
situations in which elevated IL-17 might attenuate the response to anti-TNF/anti-IL-1 therapy.
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as IL-17F, IL-17B, and IL-17E in the development of
chronic synovitis and tissue destruction during arthritis,
especially in relation to other known key cytokines (IL-1,
tumor necrosis factor [TNF], and receptor activator of
NF-κB ligand [RANKL]).
IL-17 signaling
In contrast to the restricted expression of IL-17, the IL-17
receptor (IL-17R) is ubiquitously expressed in virtually all
cells and tissues. It is a type I transmembrane protein that
has no sequence similarity to any other known cytokine
receptor [5]. The exact mechanisms of IL-17 signaling are
not fully elucidated. Binding of IL-17 to its unique receptor
results in activation of the adapter molecule TNF-receptor-
associated factor 6 (TRAF6), which is required for IL-17
signaling [12]. IL-17 shares transcriptional pathways with IL-
1 and TNF. It can activate NF-κB and all three classes of
mitogen-activated protein (MAP) kinases including
extracellular signal-related kinase (ERK)1 and ERK2, c-Jun
N-terminal kinase (JNK), and p38 [13–15]. These pathways
have been identified in synoviocytes [16] and chondrocytes
[14]. Four other receptors for the IL-17 family have been
identified so far: IL-17RH1 [8] and IL-17RL (receptor-like)
[17], IL-17RD, and IL-17RE, which share partial sequence
homology to IL-17R [18] (Table 1). The expression pattern
of these new receptors seems to be more cell/tissue-
specific than that of the IL-17R, and the ligand specificities
of many of these receptors have not been established.
Regulation of IL-17
The physiological stimulus for the induction of IL-17
expression has not been fully identified. Microbial stimuli
induced the expression of IL-17 together with TNF-α in
both murine and human T cells [19]. Cell–cell contact of
human T cells with fibroblasts resulted in increased mRNA
expression of IL-17 and IL-17R. Supernatants obtained
from cell–cell contact-stimulated peripheral blood lympho-
cytes enhance the production of IL-6 and IL-8 by
fibroblast-like synoviocytes, an effect that was blocked by
antibodies against IL-17 [20]. Furthermore, IL-15 produced
by synoviocytes is considered to be a potent inducer of
IL-17 production [21,22]. Moreover, IL-23 produced by
activated DCs and macrophages acts on memory T cells,
promoting the production of IL-17 (both IL-17 and IL-17F)
[23]. In addition, a direct role was suggested for IL-23 in
IL-17 production by CD8+ T cells [23,24]. IL-23 affects
memory T cell and inflammatory macrophage function, and
IL-23 (but not IL-12) is a critical factor in autoimmune
inflammation to the central nervous system [25].
Further support for IL-23 as an important trigger for IL-17
was obtained from studies with IL-23-specific knockout
mice [26,27]. Specific absence of IL-23 completely
prevented collagen-induced arthritis (CIA), whereas loss
of IL-12 exacerbates CIA [26]. Interestingly, resistance
was correlated with an absence of IL-17-producing CD4+
T cells despite normal induction of collagen-specific,
interferon-γ-producing T helper 1 cells. In contrast, IL-12-
deficient p35-deficient mice developed more IL-17-
producing CD4+ T cells, as well as an elevated expression
of proinflammatory cytokines (such as TNF-α, IL-1β, IL-6,
and IL-17) in affected tissues of diseased mice [26].
Importantly, IL-23-deficient mice resemble IL-17-deficient
mice phenotypically [27,28]. These studies indicate the
existence of an IL-23/IL-17 axis of communication between
the innate and adaptive parts of the immune system that
might be an interesting target for the immunotherapy of
inflammatory autoimmune diseases [26,27].
Role of IL-17 in the pathogenesis of RA
RA is a chronic systemic disorder that is characterized by
autoimmunity, infiltration of joint synovium by activated
inflammatory cells, synovial hyperplasia, neoangiogenesis
and progressive destruction of cartilage and bone. RA is
considered to be a systemic Th1-associated inflammatory
joint disease, and T cells comprise a large proportion of
the inflammatory cells invading the synovial tissue. T cell
activation and migration into the synovium occur as an
early consequence of disease, and these cells adopt a
pro-inflammatory phenotype. Considerable evidence now
supports a role for T cells in the initiation and perpetuation
of chronic inflammation prevalent in RA. Although T cells
represent a large proportion of the inflammatory cells
during inflammation, T cell-derived cytokines are much less
abundant. However, because the vast majority of these are
memory T cells, IL-17 is upregulated in early disease.
There is now considerable evidence from studies in vitro
with RA synovium and/or co-cultures that IL-17 is a pro-
inflammatory cytokine produced only by cells of the
immune system, which is thought to contribute to
inflammation associated with RA [29]. IL-17 is
spontaneously produced by RA synovial membrane
cultures, and IL-17-producing cells were found in T cell-
rich areas [30] and high levels have been detected in the
synovial fluid of patients with RA [21,30,31]. Although
Table 1
Interleukin (IL)-17 family members and their receptors
Ligand Receptor Refs
IL-17 (IL-17A) IL-17R (IL-17AR) [5,11]
IL-17B IL-17BR (IL-17RH1/IL-17ER) (low affinity) [7,8,18]
IL-17C ? [7]
IL-17D ? [80]
IL-17E IL-17ER (IL-17RH1/IL-17BR) (high affinity) [9,18]
IL-17F IL-17R + ? [10,11]
? IL-17RL (IL-17RC) [17,18]31
bioactive IL-17 is detected in RA and osteoarthritis
synovial fluid, the levels of IL-17 were found to be higher in
RA synovial fluid than in osteoarthritis synovial fluid
[30,31]. The expression of IL-17 in Th1 and Th2 cells
seems to be different depending upon the conditions.
Th1/Th0, but not Th2, subsets of CD4+ T cell clones
isolated from rheumatoid synovium produced IL-17 [32].
In contrast, IL-17 production was found in both Th1 and
Th2 clones from human skin-derived nickel-specific T cells
[33]. In mice, IL-17 is produced by T cells expressing
TNF-α but not by Th1 or Th2 cells [19]. IL-17 stimulates
transcriptional NF-κB activity and IL-6 and IL-8 secretion
in fibroblastic, endothelial, and epithelial cells, and induces
T cell proliferation [1,5]. Furthermore, it triggers human
synoviocytes to produce granulocyte/macrophage colony-
stimulating factor and prostaglandin E2 [1], suggesting
that IL-17 could be an upstream mediator in the
pathogenesis of arthritis and might have a function in fine-
tuning the inflammatory response.
T cell IL-17 also stimulates the production of IL-1 and
TNF-α from human PBMC-derived macrophages in vitro
[34]. It enhances IL-1-mediated IL-6 production by RA
synoviocytes in vitro as well as TNF-α-induced synthesis
of IL-1, IL-6, and IL-8 [35,36]. This indicates that IL-17
synergizes with IL-1 and TNF, and it has been shown that
the combination of TNF-α blockade with IL-1 and IL-17
blockade is more effective for controlling IL-6 production
in RA synovium cultures [37]. In addition, IL-17 induces
RANKL expression, which is an essential cytokine for
osteoclastogenesis and bone resorption [31]. IL-17 can
synergize with these cytokines (IL-1, TNF, and RANKL),
but probably acts directly as well. Furthermore, when IL-
17 is combined with other cytokines that are already
thought to be important in arthritic disease (such as TNF-α
and IL-1), even more marked tissue destruction occurs
[37] (Lubberts E, Koenders MI, Van den Berg WB,
unpublished data). These observations strongly implicate
IL-17 as having an important function in the disease
pathogenesis of RA (Fig. 1).
Role of IL-17 in T cell immunity and/or
propagation of joint inflammation
In arthritis, IL-17 is a pro-inflammatory cytokine thought to
contribute to the joint inflammatory process [38]. Studies
in IL-17-deficient mice revealed that IL-17 has an
important function in the activation of T cells in allergen-
specific T cell-mediated immune responses [28]. Further-
more, IL-17 has a function in the antigen-specific T cell
activation phase of CIA [39]. Of interest, CIA was
markedly but not completely suppressed in IL-17-deficient
mice. IL-17 was responsible for the priming of collagen-
specific T cells and for collagen-specific IgG2a production
[39]. In contrast, the spontaneous development of
destructive arthritis in mice deficient in IL-1 receptor
antagonist could be completely prevented after
inactivation of IL-17 [40]. In line with the situation in most
RA patients, low systemic levels of IL-17 were found after
the immunization protocol of CIA but IL-17 expression in
the synovium gradually increased after the onset of CIA
[41]. Early neutralization of endogenous IL-17 using the IL-
17 receptor IgG1 Fc fusion protein starting after the
immunization protocol during the initial phase of arthritis
suppresses the onset of experimental arthritis [41].
Moreover, neutralizing endogenous IL-17 with anti-IL-17
sera after the onset of CIA still diminished the severity of
CIA [42]. Histological analysis confirmed the suppression
of joint inflammation, and systemic IL-6 levels were
significantly decreased after treatment with anti-IL-17
antisera. In contrast, systemic as well as local IL-17
overexpression using an adenoviral vector expressing
murine IL-17 accelerated the onset of CIA and aggravated
synovial inflammation at the site [41,43]. These
observations strongly implicate a role for IL-17 at various
levels in disease pathogenesis of arthritis. IL-17 seems to
have a function in T cell immunity and in the propagation
of joint inflammation.
Role of IL-17 in cartilage destruction
IL-17 has dual effects on cartilage. This T cell cytokine
inhibits chondrocyte metabolism in intact articular
Available online http://arthritis-research.com/content/7/1/29
Figure 1
Schematic overview of interleukin-17 (IL-17) in relation to other key
cytokines in the pathogenesis of arthritis. RANKL, receptor activator of
NF-κB ligand; TNF, tumor necrosis factor.32
cartilage of mice and induces proteoglycan breakdown
(Table 2) [44–47]. Furthermore, studies in vitro showed
the induction of metalloproteinases by IL-17 in
synoviocytes and chondrocytes [48–50]. Interestingly, the
IL-17 family subtypes IL-17F and IL-17E also showed
cartilage destructive potential in vitro [11,47] (Table 2).
Another IL-17 family member, IL-17B, has been shown to
be expressed by chondrocytes in normal bovine articular
cartilage, mostly in the mid and deep zones [18].
IL-17 shares biological activities with IL-1, which is a key
cytokine in the induction of cartilage destruction [51]. In
vitro, IL-17 suppresses matrix synthesis by articular
chondrocytes through enhancement of nitric oxide
production [45,52–54]. However, it has been shown that
the effects of IL-17 on matrix degradation and synthesis
were not dependent on IL-1 production by chondrocytes
and IL-1Ra did not block IL-17-induced matrix release nor
did they prevent the inhibition of matrix synthesis in vitro
with pig articular cartilage explants [47]. In contrast, the
IL-17-induced production of prostaglandin E2 and nitric
oxide by cartilage explants is dependent on leukemia
inhibitory factor [47,54]. Interestingly, an IL-1-independent
role of IL-17 in the pathogenesis of experimental arthritis
was demonstrated [41]. The downstream signaling
pathways for IL-17 and IL-1 seem to be distinct, and
differential activation of activator protein 1 (AP-1)
members by IL-17 and IL-1β has been described [49].
Although IL-1 is by far the more catabolic cytokine in
experimental arthritis in comparison with TNF-α, the
combination of IL-17 and TNF-α synergizes to induce
cartilage destruction in vitro [55] as well as in vivo
(Lubberts E, unpublished data). These data suggest that
IL-17 alone or in combination with TNF-α might
circumvent the catabolic effects of IL-1 on cartilage.
Interrelation between IL-17,
polymorphonuclear cell influx, and cartilage
destruction
In mice, local overexpression of IL-17 in the knee joint of
both naive mice and mice immunized with type II collagen
(CII) leads to enhanced influx of polymorphonuclear cells
(PMNs) [41]. A main difference between IL-17 over-
expression in naive and CII-immunized DBA-1 mice was
the observation that, in CIA, PMNs were heavily sticking to
patella and femur cartilage, a phenomenon that was not
observed in naive mice. Interestingly, under both
conditions, local IL-17 induced proteoglycan depletion
(Table 2). However, no chondrocyte death and cartilage
erosion was observed in naive mice after local IL-17 gene
transfer (Table 2). In contrast, local IL-17 aggravates
cartilage erosion in CIA [41].
The lack of irreversible cartilage destruction under naive
conditions in contrast to CIA conditions might be due to
the lack of immune complexes formed during IL-17-
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induced joint inflammation in normal mice. Although IL-17
overexpression induced enhanced synovial stromelysin
(pro-matrix metalloproteinase [pro-MMP]-3) expression
under naive as well as CIA conditions (Lubberts E,
unpublished data), the presence of immune complexes
might be required for the cleavage process of pro-MMPs
into active MMPs. This phenomenon is not well under-
stood.
The elevated neutrophil influx and subsequent sticking to
anti-CII immune complexes in the cartilage surface layer
during CIA probably releases oxygen species and
proteolytic enzymes present in PMNs directly into the
surface of cartilage, thereby escaping inhibitors present in
the synovial fluid [41,56,57]. IL-17 might enhance immune
complex formation in CIA because IL-17 has a crucial
function in activating autoantigen-specific cellular and
humoral immune responses [39].
In contrast to aggravation of cartilage damage by IL-17
overexpression, neutralizing endogenous IL-17 in arthritis
models protects against cartilage destruction. Both
reversible proteoglycan depletion and the irreversible
cartilage markers chondrocyte death and cartilage surface
erosion were suppressed after neutralizing IL-17 after the
onset of CIA [42]. A reduced influx of PMNs was noted
and fewer IL-1β-positive cells were detected in the
synovial infiltrate after treatment with anti-IL-17 antibody
[42]. Furthermore, the induction of chronic relapsing
streptococcal cell wall-induced arthritis in mice deficient in
the IL-17 receptor (IL-17R) revealed the critical role for T
cell IL-17/IL-17R signaling in driving synovial IL-1
expression and different metalloproteinases (Koenders MI,
Kolls JK, Van den Berg WB, Lubberts E, unpublished
data). These observations suggest that the presence of T
cell IL-17 in the synovial infiltrate has major influences on
PMN influx, synovial IL-1 expression, and the cartilage
destructive process. IL-17 therefore seems to be a
significant target for the treatment of cartilage destruction
in T cell-mediated arthritis.
Role of IL-17 in bone erosion
In addition to the role of IL-17 in cartilage destruction, this
T cell cytokine is a potent stimulator of osteoclastogenesis
(Fig. 2). Promotion of type I collagen degradation in
synovium and bone by IL-17 has been demonstrated, and
when combined with IL-1, a marked synergistic release of
collagen was noted [44]. IL-17 in combination with TNF-α
increased osteoclastic resorption in vitro [58]. Further-
more, IL-17 induced the expression of RANKL in cultures
of osteoblasts [31]. RANKL is a crucial regulator of
osteoclastogenesis [59]. RANKL binds to its unique
receptor activator of NF-κB (RANK) [60], and the RANKL/
RANK pathway seems of crucial importance in osteo-
clastogenesis and the bone erosion process. RANKL and
the decoy receptor osteoprotegerin [61] are important
positive and negative regulators of osteoclastogenesis
and bone resorption. Regulation of IL-17 and RANKL, as
shown by IL-4 gene therapy in collagen arthritis, prevents
osteoclastogenesis and bone erosion [62]. Systemic
treatment with a soluble IL-17 receptor fusion protein (sIL-
17R:Fc) starting before arthritis expression in experimental
arthritis prevented bone erosion [41,63]. Moreover,
development of bone erosion in the chronic relapsing
streptococcal cell wall-induced arthritis model in IL-17R-
deficient mice was significantly suppressed (Lubberts E,
Van den Berg WB, Kolls JK, unpublished data). In
contrast, local IL-17 overexpression in the knee joint of CII-
immunized mice resulted in promotion of collagen arthritis
and aggravated joint destruction [43,64]. In the CIA model
it was shown that IL-17 promoted bone erosion through
loss of the RANKL/osteoprotegerin balance [64]. Systemic
treatment with osteoprotegerin prevented joint damage
induced by local IL-17 gene transfer in CII-immunized
mice. This strongly suggests that IL-17 is a potent inducer
of RANKL and that the IL-17-induced promotion of bone
erosion is strongly mediated by RANKL.
Interrelation between IL-17 and IL-1/TNF
Overexpression of IL-17 in the mouse knee joint of CII-
immunized mice resulted in elevated levels of IL-1β protein
in the synovium [41]. Intriguingly, blocking of IL-1α/β with
neutralizing antibodies had no effect on the IL-17-induced
synovial inflammation and joint damage, implying an IL-1-
independent pathway [41]. This direct potency of IL-17
was underscored in the unabated IL-17-induced
exaggeration of bacterial cell wall-induced arthritis in
IL-1β-deficient mice [41]. Apart from IL-1, synergistic
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Figure 2
Schematic overview of the mechanism of interleukin-17 (IL-17) in bone
resorption. The interrelationship of IL-17 with receptor activator of
NF-κB ligand (RANKL), IL-1, tumor necrosis factor (TNF) and the
modulatory role of IL-4 and osteoprotegerin (OPG) is presented. OC,
osteoclast.34
effects between IL-17 and TNF in systems in vitro have
been reported regarding cytokine induction and cartilage
damage [44,55]. Because in mice IL-17-producing T cells
also express TNF-α we performed blocking studies with
IL-17 and TNF inhibitors. In line with the observations in
vitro with RA synovial co-cultures [37], a combination
blockade of TNF-α and IL-17 suppressed continuing CIA
and was more effective than neutralizing TNF alone
(Lubberts E, Van den Berg WB, unpublished data). It is of
interest that TNF-α-dependent arthritis can be
circumvented by IL-17 (Koenders MI, Lubberts E, Van den
Berg WB, unpublished data). This underscores the
potential of IL-17 to act additively or even synergistically
with IL-1/TNF. Moreover, it also shows that T cell IL-17
can replace the proinflammatory/catabolic function of IL-1/
TNF, directly or through interplay with other macrophage-
driven factors.
Role of IL-17 in other
inflammatory/autoimmune diseases
Apart from the role of IL-17 in autoimmune arthritis, IL-17
and its family members exhibit a potential role in other
inflammatory diseases, such as lung, gut, and skin
inflammation [65–69]. IL-17 has a function in T-cell-
triggered inflammation by stimulating stromal cells to
secrete various cytokines and growth factors associated
with inflammation [1,2]. IL-17 regulates gene expression
and protein synthesis of the complement system [70]. It
has a regulatory role on C3 expression and synthesis and
an amplifying effect on TNF-induced factor B synthesis
[70]. In addition, IL-17 stimulates granulopoiesis and is a
strong inducer of neutrophil recruitment through chemo-
kine release [65,71]. Furthermore, IL-17 promotes angio-
genesis [72] and a role for IL-17 was suggested in
allogeneic T cell proliferation that might be mediated in
part through a maturation-inducing effect on dendritic
cells (DC) [73]. Studies in IL-17-deficient mice revealed
that this T cell cytokine had an important function in the
activation of T cells in allergen-specific T cell-mediated
immune responses [28]. IL-17 induced neutrophil
accumulation in infected lungs. Greatly diminished recruit-
ment of neutrophils into lungs was found in mice with
homozygous deletion of the IL-17 receptor in response to
a challenge with a Gram-negative pathogen [74].
Overproduction of IL-17 has been associated with several
chronic disease conditions, suggesting a role of IL-17 in
these diseases. IL-17E transgenic mice showed growth
retardation, jaundice, a Th2-biased response, and multi-
organ inflammation [75]. Furthermore, IL-17 expression
was observed in ovarian, endometrial, and cervical
cancers exhibiting angiogenic effects [76,77]. Elevated
levels of IL-17 were found in other autoimmune diseases,
such as experimental autoimmune encephalomyelitis [78],
and in patients with systemic sclerosis [79]. However,
further studies are needed to unravel the role of IL-17 in
the pathogenesis of these autoimmune inflammations.
Conclusions
IL-17 is a T cell-derived cytokine produced by activated
T cells, predominantly by activated CD4+CD45RO+
memory cells, and is expressed in the synovium of patients
with RA. IL-17 has a function in T cell-triggered
inflammation by stimulating different cell types to secrete
various cytokines and chemokines. In addition, IL-17
shows additive or even synergistic effects with IL-1 and
TNF in inducing cytokine expression and joint pathology.
Furthermore, T cell IL-17 is a potent inducer of RANKL, a
crucial cytokine in osteoclastogenesis and bone resorption.
IL-17 can act together with these cytokines but has direct
pathological effects as well. It has been shown that IL-17
has IL-1-independent activities in inducing synovial
inflammation and joint destruction in experimental arthritis.
Furthermore, IL-17 has a function in prolongation of the
arthritis process and can be considered an important
target for the treatment of destructive arthritis.
The discovery of IL-17 family members may further extend
the role of this cytokine family in arthritis pathology. IL-17F
showed similar biological effects to those of IL-17;
however, IL-17F is expressed in activated monocytes in
addition to activated T cells. Further studies will be
required to determine the contribution and precise
mechanism of action of the novel IL-17 family member(s),
with emphasis on the interaction with other known key
cytokines in the pathogenesis of arthritis. Furthermore, IL-
23 seems to be an important physiological stimulus for the
induction of IL-17 and IL-17F, although other mediators
might also be involved [21,23,26,27].
Results so far suggest strongly that IL-17 is a novel target
for the treatment of destructive arthritis. Because it is
known that this T cell factor can have synergistic effects
with catabolic/inflammatory mediators, it is tempting to
speculate that IL-17 levels can influence whether or not a
patient will respond to anti-TNF and anti-IL-1 therapy. Anti-
IL-17 cytokine therapy might be an interesting new anti-
rheumatic approach that could contribute to the
prevention of joint destruction as an adjunct to anti-TNF
and anti-IL-1 therapy.
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